SCHEMBL63763

SCHEMBL63763

CN(C)C(=O)C(=O)N1CCCC1C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.52
KCNH2 Q12809 1/20 0.49
ALDH1A1 P00352 2/20 0.41
KCNE1 P15382 1/20 0.35
CCR1 P32246 1/20 0.35
KCNQ1 P51787 1/20 0.35
CALCA P06881 1/20 0.34
CYP3A4 P08684 1/20 0.34
PKM P14618 1/20 0.34
CYP2C19 P33261 1/20 0.34
GLA P06280 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33
ERCC1 P07992 1/20 0.33
FEN1 P39748 1/20 0.33
ERCC4 Q92889 1/20 0.33
F2 P00734 2/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63762 0.92 KCNH2 (0.48) CYP2C9KCNH2ALDH1A1KCNE1CCR1
SCHEMBL62603 0.92 KCNH2 (0.48) CYP2C9KCNH2ALDH1A1KCNE1CCR1
SCHEMBL64070 0.90 KCNH2 (0.47) CYP2C9KCNH2ALDH1A1KCNE1CCR1
SCHEMBL62825 0.90 KCNH2 (0.47) CYP2C9KCNH2ALDH1A1KCNE1CCR1
SCHEMBL63134 0.90 KCNH2 (0.48) CYP2C9KCNH2ALDH1A1KCNE1CCR1
SCHEMBL87188 0.90 KCNH2 (0.48) CYP2C9KCNH2ALDH1A1KCNE1CCR1
SCHEMBL63630 0.90 KCNH2 (0.46) CYP2C9KCNH2ALDH1A1KCNE1CCR1
SCHEMBL64080 0.89 KCNH2 (0.46) CYP2C9KCNH2ALDH1A1KCNE1CCR1
SCHEMBL63389 0.89 CYP2C9 (0.49) CYP2C9KCNH2ALDH1A1KCNE1CCR1
SCHEMBL64388 0.89 KCNH2 (0.49) CYP2C9KCNH2ALDH1A1KCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG CYP2C9 602/4885KCNH2 3969/4885ALDH1A1 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.